Digest Network Come funziona
Network
/
Società
Ve
Non verificato

Verastem Oncology

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

57 comunicati stampa

Guarda tutti i comunicati
12/01/2026
Biotecnologia
Salute
Farmaceutica
Medicina - Varie
Oncologia
Mercato azionario
Finanza
Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
29/12/2026
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Industria
Verastem Oncology Provides Update on RAMP 203 Phase 1/2 Clinical Trial for Advanced KRAS G12C Mutant Non-Small Cell Lung Cancer
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
15/12/2025
Mercato del lavoro
Oncologia
Salute
Medicina - Varie
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces Strategic Transition Plan to Accelerate Next Phase of Growth
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
25/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Eventi
Web e Social Network
Verastem Oncology to Present at the 8th Annual Evercore Healthcare Conference
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
14/11/2025
Biotecnologia
Farmaceutica
Salute
Oncologia
Finanza
Verastem Oncology Announces Pricing of $90 Million Public Offering of Common Stock and Pre-Funded Warrants
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
13/11/2025
Finanza
Oncologia
Igiene alimentare
Salute
Sanità
Farmaceutica
Biotecnologia
Verastem Oncology Announces Proposed Public Offering of Common Stock
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
04/11/2025
Web e Social Network
Telefonia e Varie
Mercato azionario
Biotecnologia
Igiene alimentare
Salute
Farmaceutica
Oncologia
Verastem Oncology Reports Third Quarter 2025 Financial Results and Highlights Recent Business Updates
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
23/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Analisi di mercato
Industria
Verastem Oncology Announces Encouraging Preliminary Data from Ongoing Phase 1/2a Dose Escalation Trial of VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, in Patients with KRAS G12D Mutant Solid Tumors
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
23/10/2025
Oncologia
Salute
Medicina - Varie
Scienza
Farmaceutica
Biotecnologia
Web e Social Network
Telefonia e Varie
Finanza
Mercato azionario
Verastem Oncology to Report Third Quarter 2025 Financial Results on November 4, 2025
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0
19/10/2025
Oncologia
Salute
Scienza
Farmaceutica
Biotecnologia
Eventi
Industria
Verastem Oncology Announces Updated Data from Partner GenFleet Therapeutics’ Phase 1/2 Monotherapy Study in China of GFH375 (VS-7375) in Advanced KRAS G12D Mutant Pancreatic Ductal Adenocarcinoma
Fonte
Verastem Oncology
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0